Vericiguat is a medicine used for heart failure, when the heart doesn't pump as strongly as it should. It is taken as a pill once a day. It works by helping blood vessels relax so the heart can pump more easily.
Every report comes from a Lived member, sent anonymously.
Have you tried Verquvo (Vericiguat) for Systolic Heart Failure?
Vericiguat, sold as Verquvo, is a once-daily prescription tablet for adults with chronic heart failure whose heart muscle pumps weakly. It is meant for a specific group: people with symptoms whose ejection fraction (the share of blood the main pumping chamber pushes out with each beat, measured on an echocardiogram or similar scan) is below 45%, and whose heart failure has recently worsened enough to need a hospital stay or diuretic medicine given through a vein as an outpatient. The goal is to lower the chance of dying from heart-related causes or being hospitalized again for heart failure. Vericiguat is added to the usual heart failure medicines, such as beta blockers and drugs that act on the hormone systems controlling blood pressure and fluid, rather than replacing them. It is not approved for children.
Nitric oxide is a signaling molecule that tells blood vessel walls and heart muscle to relax. It does this by switching on an enzyme called soluble guanylate cyclase, which produces a messenger chemical (cGMP) inside the cells. In heart failure, this pathway tends to run weakly, which is thought to contribute to stiff blood vessels and a strained, enlarged heart. Vericiguat stimulates that enzyme directly, both on its own and alongside whatever nitric oxide is present, so more of the messenger is made. The result is relaxed blood vessels and less work for the heart. Its effect on blood pressure is small on average, only about 1 to 2 points lower on the top number than placebo in its main trial, which is part of why it can be layered onto other heart failure treatment.
Vericiguat comes as tablets of 2.5 mg, 5 mg and 10 mg, taken once a day with food. Treatment starts low, at 5 mg or at 2.5 mg for people more prone to low blood pressure, and the dose is usually doubled about every two weeks until reaching 10 mg, if blood pressure and symptoms allow. Most people in the main trial reached the full dose within about a year. For anyone who has trouble swallowing pills, the tablet can be crushed and mixed with water just before taking it. If a dose is missed, take it later the same day once you remember, but never take two doses on the same day.
Low blood pressure is the most common side effect and is most likely in the first weeks or after a dose increase. It can show up as dizziness or lightheadedness, especially when standing up quickly. Mention these to the care team, since the dose may need to stay lower or other medicines may need adjusting; fainting should be reported promptly. Anemia, a lower red blood cell count, was also more common with vericiguat than with placebo (about 10% compared with 7%). It can add to tiredness or shortness of breath, which overlap with heart failure symptoms, so routine blood tests help tell the two apart.
Vericiguat carries a boxed warning, the most prominent kind the US Food and Drug Administration (FDA) requires, because animal studies showed it can cause serious birth defects, including heart malformations. It must not be taken during pregnancy. Anyone who could become pregnant needs a pregnancy test before starting and should use effective birth control during treatment and for one month after the last dose. A known or suspected pregnancy should be reported to the prescriber right away. Breastfeeding is not recommended while taking it. It must not be combined with riociguat (Adempas), a related medicine for certain types of high blood pressure in the lungs that works on the same enzyme. Combining it with sildenafil (Viagra, Revatio), tadalafil (Cialis) or similar drugs for erectile dysfunction or lung blood pressure is not recommended, because together they can drop blood pressure too far. Short-acting nitroglycerin for chest pain was well tolerated in people with heart failure, though experience with long-acting nitrates is limited, so keep the prescriber aware of any heart medicines added later.
Vericiguat is not designed to make people feel noticeably different, and any change in breathlessness or energy is usually gradual. Its value is measured over time in fewer serious setbacks. In the main trial, about 5,000 people with a recent worsening event were followed for a median of 11 months. Each year, roughly 34 of every 100 people on vericiguat had a heart-related death or a first heart failure hospitalization, compared with about 38 of every 100 on placebo. The difference came mostly from fewer hospital stays; the reduction in heart-related deaths alone was not statistically clear. People with extremely high levels of NT-proBNP, a blood marker of heart strain, did not appear to benefit. A later trial in people whose heart failure had been stable, without a recent hospital stay, did not show a clear reduction in the same combined outcome, which is why the approval remains limited to people after a worsening event. During the first weeks, expect blood pressure checks around each dose increase. After that, it is a long-term medicine reviewed at regular heart failure visits, alongside blood tests and checks on kidney function and symptoms. It has not been studied in people on dialysis or with very low kidney function.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Verquvo (Vericiguat), what you've noticed, or ask the community a question.